Celldex Therapeutics
CLDX
134 hedge funds and large institutions have $295M invested in Celldex Therapeutics in 2017 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 44 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
11% more call options, than puts
Call options by funds: $1.4M | Put options by funds: $1.27M
1% more capital invested
Capital invested by funds: $293M → $295M (+$2.64M)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
0.19% less ownership
Funds ownership: 4.56% → 4.37% (-0.19%)
5% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 44
4% less funds holding
Funds holding: 140 → 134 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$28.1M |
| 2 |
MG
Meditor Group
Hamilton,
Bermuda
|
+$14.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.44M |
| 4 |
Renaissance Technologies
New York
|
+$1.76M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$3.35M |
| 3 |
Millennium Management
New York
|
-$3.18M |
| 4 |
DM
Deerfield Management
New York
|
-$2.24M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.76M |
CLDX Hedge Fund Activity: Q1 2017 in Review
134 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2017, worth a combined $295M — up 0.9% from $293M a quarter earlier.
Fund positioning in CLDX was balanced in Q1 2017: 19 funds opened new positions, 19 closed out, 42 added to existing stakes and 44 trimmed.
The largest buyer was BlackRock, adding an estimated $28.1M. The largest seller was Fidelity Investments, cutting an estimated $18.1M.
- 134 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2017, down from 140 in Q4 2016.
- Funds reported $295M of Celldex Therapeutics stock for Q1 2017, up 0.9% quarter-over-quarter.
- 19 funds opened new Celldex Therapeutics positions in Q1 2017 and 19 closed out, a net change of 0 holders.
- The largest Celldex Therapeutics buyer in Q1 2017 was BlackRock, an estimated $28.1M added.
- The largest Celldex Therapeutics seller in Q1 2017 was Fidelity Investments, an estimated $18.1M sold.
Based on aggregated 13F filings for Q1 2017.